MedTrace Logo

Molecular Profiling Protocol (SCRI-CA-001)

NCT00530192 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2009-07-10

No results posted yet for this study

Summary

This is an open-label, multicenter pilot study in patients with advanced solid tumors.

The primary objective of this study is to compare progression-free survival using a treatment regimen selected by molecular profiling with progression-free survival for the most recent regimen the patient has progressed on.

To be eligible, patients must have received at least two lines of prior chemotherapeutic, hormonal or biological regimens for advanced disease, have measurable or evaluable, refractory disease and have clear documentation of the time between treatment start and documented progression on the last treatment prior to study entry. Eligible patients must undergo or have available a tumor biopsy for molecular profiling within 2 months of IHC/FISH and/or DNA microarray analysis.

Conditions

  • Refractory Cancer

Interventions

OTHER

Treatment based on Molecular Profiling

Treatment with commercially available treatments (per package insert instructions)

Sponsors & Collaborators

  • Translational Genomics Research Institute

    collaborator OTHER

  • Scottsdale Healthcare

    lead OTHER

Principal Investigators

  • Daniel D Von Hoff, MD · TGen Clinical Research Services at Scottsdale Healthcare

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00530192 on ClinicalTrials.gov